[243] Attorney Docket No.: AGI-131.2US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant

Brown et al.

Serial No.

Not Yet Assigned

Filed

Simultaneously Herewith

For

DERMATOLOGICAL COMPOSITIONS AND

METHODS

INFORMATION DISCLOSURE STATEMENT

In accordance with 37 CFR §1.56 and 37 CFR §1.97(b)(1), applicants wish to call the Examiner's attention to the references listed on the Modified 1449 Form submitted herewith.

Pursuant to 37 CFR §1.98(d), copies of the references on the 1449 form are not being submitted herewith since each of the references was previously cited by or submitted to the Patent Office in prior application Serial No. 09/085,917, filed on May 28, 1998, from which this application claims priority under 35 U.S.C. §120. However, if for any reason, the Examiner believes it is necessary or desirable for applicants to provide copies of all or some of these references, the Examiner is requested to advise the undersigned attorney and any copies required will be provided.

The Examiner is respectfully requested to initial a copy of the Modified 1449 Form and return it to applicants to indicate consideration of the references listed thereon in connection with the prosecution of this application.

Respectfully submitted.

Date: 9/22/03

raunie Klee

Maurice M. Klee, Ph.D.

Reg. No. 30,399

Attorney for Applicant

1951 Burr Street Fairfield, CT 06824

 $(203)\ 255-1400$

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant

David A. Brown, Alexander A. Khorlin, Krystyna Lesiak

and Wu Yun Ren

Serial No.

Not Yet Assigned

Filed

Simultaneously Herewith

For

DERMATOLOGICAL COMPOSITIONS AND

METHODS

MODIFIED 1449 FORM

U.S. PATENT DOCUMENTS


Examiner <u>Initial</u>		Document Number	Issue <u>Date</u>	<u>Name</u>
	1.	3,956,361	5/1976	Stephen
	2.	4,102,995	7/1978	Hebborn
	3.	4,104,203	8/1978	Hall et al.
	4.	4,390,532	6/1983	Stüttgen et al.
	5.	4,528,126	7/1985	Bruns et al.
	6.	4,647,585	3/1987	Loots et al.
	7.	5,041,485	8/1991	Eichenauer et al.
	8.	5,068,453	11/1991	Kuwahara et al.
	9.	5,130,136	7/1992	Shono et al.
	10.	5,232,688	8/1993	Ziegler et al.
	11.	5,302,378	4/1994	Crotty et al.
	12.	5,352,440	10/1994	Gilchrest et al.
	13.	5,414,019	5/1995	Gould et al.

 14.	5,532,001	7/1996	Gilchrest et al.
 15.	5,554,359	9/1996	Fuller
 16.	5,574,195	11/1996	Chastain et al.
 17.	5,587,402	12/1996	Gould et al.
 18.	5,591,423	1/1997	Fuller
 19.	5,602,184	2/1997	Myers et al.
 20.	5,626,839	5/1997	Scales-Medeiros
 21.	5,698,184	12/1997	Pickart
 22.	5,700,450	12/1997	Gilchrest et al.
 23.	5,990,177	11/1999	Brown
 24.	6,214,888 B1	4/2001	Ren et al.
 25.	6,231,837 B1	5/2001	Stroud et al.
 26.	6,267,948 B1	7/2001	Ren et al.
 27.	6,294,585 B1	9/2001	Brown


FOREIGN PATENT DOCUMENTS


Examiner <u>Initial</u>		Document <u>Number</u>	<u>Date</u>	Country
	28.	0 643 113	3/1995	EP
	29.	1 200 862	8/1970	GB
	30.	WO 87 04617	7/1987	PCT
	31.	WO 89 00853	2/1989	PCT


	32.	WO 96 09810	4/1996	PCT
	33.	WO 96/26711	9/1996	PCT
	34.	WO 97 03170	1/1997	PCT
	35.	WO 97 30692	8/1997	PCT
	36.	WO 98 55085	12/1998	PCT
	37.	WO 98/11882	3/1998	PCT
	38.	WO 99 08654	2/1999	PCT
Examiner <u>Initial</u>		<u>OTHER</u>	ART	
	39.	cAMP Responses	of Cultured Ne Commonly Used	Melanogenic, and onatal Human Mitogens," <u>J. Cell.</u>
	40.	Allan et al., "Top Increase Pigmen <u>Dermatol.,</u> 1995,	tation in Guine	Diacylglycerols a Pig Skin," <u>J. Invest.</u>
	41.		induced Murine	ffects of Perillyl Skin Cancer and AP- <u>arch</u> , 1998, 58:711-
	42.	Baudouin et al., Is Present in Non Invest. Dermatol	rmal Human Ke	- · · —
	43.	Quantitation of N	Microgram Quar aciple of Protein	tive Method for the ntities of Protein a-Dye Binding," <u>Anal.</u>



 52.	Eller et al., "DNA damage enhances melanogenesis," Proc. Natl. Acad. Sci., 1996, 93:1087-1092.
 53.	Friedmann et al., "Ultraviolet Radiation Directly Induces Pigment Production by Cultured Human Melanocytes," <u>J. Cell. Physiol.</u> , 1987,133:88-94.
 54.	Fuller et al., "Hormonal Regulation of Melanogenesis in Mouse Melanoma and in Human Melanocytes," Ann. NY Acad. Sci., 1993, 690:302-319.
 55.	Fuller et al., "Regulation of Tyrosinase in Mouse Melanoma Cells and in Human Melanocytes by PKC and PKA Pathways," <u>Pigment Cell Res.</u> , 26 th International Pigment Cell Conference Abstacts, 1996, S5:65.
 56.	Garvey et al., "Potent and Selective Inhibition of Human Nitric Oxide Synthases," <u>J. Biol. Chem.</u> , 1994, 269:26669-26676.
 57.	Gates et al.,"Comparison of skin color with melanin content," <u>J. Invest. Dermatol.</u> , 1953, 21:339-348.
 58.	Gilchrest et al., "Mechanisms of Ultraviolet Light-Induced Pigmentation," <u>Photochem. Photobiol.</u> , 1996, 63:1-10.
 59.	Haag et al., "Mammary carcinoma regression induced by perillyl alcohol, a hydroxilated analog of limonene," <u>Cancer Chemotherapy and Pharmacology</u> , 1994, 34:477-483.
 60.	Hasenfratz "Experience in the treatment of acne vulgaris with the preparation acne-medice," <u>Asthetische Medizin</u> , 15:206-208, 1966.
 61.	He et al., "Isoprenoids Suppress the Growth of Murine B16 Melanomas In Vitro and In Vivo," <u>J. Nutr.</u> , 1997, 127:668-674.







¹ This English translation was provided to the prior assignee of this application by a competitor. Applicant has not made an independent translation and does not know whether this translation is accurate or not.

 90.	Schmidt et al., "Determination of Nitric Oxide via Measurement of Nitrite and Nitrate in Culture Media," 1995, <u>Biochemica</u> 2:22.
 91.	Shi et al., "Induction of differentiation in neuro-2A cells by the monoterpene perillyl alcohol," <u>Cancer Letters 95</u> , 1995, 1-6.
92.	Shoff et al., "Concentration-dependent Increase of Murine P388 and B16 Population Doubling Time by the Acyclic Monoterpene Geraniol," <u>Cancer Research</u> , 1991, 41:37-42
 93.	Siracký et al., "Relationship between melanogenesis, proliferative activity and response to chemotherapy of human melanoma xenografts," <u>Neoplasia</u> , 1984, 31:545-549, .
 94.	Southan et al., "Isothioureas: potent inhibitors of nitric oxide synthases with variable isoform selectivity," <u>Br. J. Pharmacol.</u> , 1995, 114:510-516.
 95.	Toullec et al., "The Bisinodylmaleimide GF 109203X is a Potent and Selective Inhibitor of Protein Kinase C," J. Biol. Chem., 1991, 266:15771-15781.
 96.	Uçar, K., "The effects of histamine H2 receptor antagonists on melanogenesis and cellular proliferation in melanoma cells in culture," <u>Biochem. Biophys. Res. Commun.</u> , 1991, 177:545-550.
 97.	Uchida et al., "Electrochemical oxidation of polycyclic cyclopropanes and camphene," <u>Chemical Abstracts</u> , Volume 112, No. 198816t, 1990.
 98.	Wintzen et al., "Proopiomelanocortin, Its Derived Peptides, and the Skin," <u>J. Invest. Dermatol.</u> , 1996, 106:3-10.